NatWest Group’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

NatWest Group’s Portfolio SGNT Stock Details SGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-31,280	Closed	-$480K	–	395
2015 Q3	$480K	Buy	31,280 +477	+2%	+$10.3K	0.01%	284
2015 Q2	$749K	Sell	30,803 -477	-2%	-$11.4K	0.01%	212
2015 Q1	$727K	Sell	31,280 -7,263	-19%	-$192K	0.01%	268
2014 Q4	$968	Buy	38,543 +3,485	+10%	+$102K	0.01%	218
2014 Q3	$1.09K	Buy	35,058 +12,915	+58%	+$350K	0.01%	247
2014 Q2	$573K	Buy	22,143 +4,810	+28%	+$107K	0.02%	335
2014 Q1	$405K	Sell	17,333 -376	-2%	-$8.22K	0.02%	363
2013 Q4	$449K	Buy	17,709 +3,788	+27%	+$85.5K	0.01%	589
2013 Q3	$284K	Buy	13,921 +784	+6%	+$17.5K	0.01%	905
2013 Q2	$276K	Buy	+13,137	New	+$235K	﹤0.01%	687

Other funds holding SGNT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NatWest Group's SGNT Position: Q4 2015 in Review

NatWest Group sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2015, closing a stake of 31,280 shares — an estimated $480K sold.

NatWest Group first reported a position in SGNT in Q2 2013 and held it in 10 quarters. The position peaked at $749K in Q2 2015. 134 funds tracked by Wall St. Rank hold SGNT as of Q4 2015.

NatWest Group reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 31,280 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2015, an estimated $480K.
NatWest Group first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 10 quarters.
NatWest Group's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $749K in Q2 2015.
134 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.